AstraZeneca makes ZEGFROVY available in US for certain lung cancers
The indication covers adults with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
GetSignal AstraZeneca PLC AZN
AstraZeneca announced on October 22, 2026 that ZEGFROVY (sunvozertinib) is now available in the US for adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Key facts
- Product
- ZEGFROVY (sunvozertinib)
- Availability
- US
- Announced
- October 22, 2026
- Indication
- Locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, previously treated with platinum-based chemotherapy
Source: The company's release on Business Wire, October 22, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
